RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Stock List・Lonza Group AG

Lonza Group AG

Closed

SectorHealthcare

493.4 3.09

Buy Sell

Overview

Share price change

24h

Current

Min

478.65

Max

494.2

Key metrics
By Trading Economics
Income	57M 483M
Sales	-621M 3B
P/E Sector Avg	37.585 67.147
Dividend yield	1.04
Profit margin	16.345
Employees	20,000
EBITDA	-181M 822M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+37.73% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	1.04% 2.36%
Next Earnings	22 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-4.6B 34B
Previous open	490.31
Previous close	493.4

News Sentiment

By Acuity

14%

86%

24 / 347 Healthcare

Lonza Group AG Chart

Past performance is not a reliable indicator of future results.

Related News

6 Mar 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

28 Jan 2026, 06:15 UTC

Earnings

Lonza Sales Grow on New Contract Momentum

23 Jul 2025, 08:30 UTC

Earnings

Major Market Movers

Lonza Shares Rise After Outlook Lift for Core Business

9 Mar 2026, 10:34 UTC

Market Talk

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

6 Mar 2026, 17:12 UTC

Acquisitions, Mergers, Takeovers

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

6 Mar 2026, 17:10 UTC

Acquisitions, Mergers, Takeovers

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

6 Mar 2026, 17:09 UTC

Acquisitions, Mergers, Takeovers

Lonza to Retain 40% Stake in CHI

6 Mar 2026, 17:08 UTC

Acquisitions, Mergers, Takeovers

Lonza Will Receive Upfront Proceeds of CHF1.7B

6 Mar 2026, 17:07 UTC

Acquisitions, Mergers, Takeovers

Lonza: Transaction Expected to Close in 2H

6 Mar 2026, 17:07 UTC

Acquisitions, Mergers, Takeovers

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

6 Mar 2026, 17:06 UTC

Acquisitions, Mergers, Takeovers

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

28 Jan 2026, 12:04 UTC

Market Talk

Earnings

Lonza Results Show a Company in Good Shape -- Market Talk

28 Jan 2026, 05:35 UTC

Earnings

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

28 Jan 2026, 05:34 UTC

Earnings

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

28 Jan 2026, 05:33 UTC

Earnings

Lonza Issues 2026 View

28 Jan 2026, 05:32 UTC

Earnings

Lonza 2025 Core Ebitda Margin 31.6%

28 Jan 2026, 05:32 UTC

Earnings

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

28 Jan 2026, 05:32 UTC

Earnings

Lonza 2025 Core Ebitda CHF2.06B

28 Jan 2026, 05:30 UTC

Earnings

Analysts Saw Lonza 2025 Sales at CHF7.54B

28 Jan 2026, 05:30 UTC

Earnings

Lonza 2025 Sales CHF6.53B

27 Oct 2025, 08:24 UTC

Market Talk

Lonza on Track to Meet Long-Term Goals -- Market Talk

23 Oct 2025, 10:53 UTC

Market Talk

Earnings

Lonza Set to Recover as Contracts Flow in -- Market Talk

23 Jul 2025, 08:00 UTC

Market Talk

Earnings

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23 Jul 2025, 04:44 UTC

Earnings

Lonza 1H Sales Grew 19% at Constant Currency

23 Jul 2025, 04:43 UTC

Earnings

Lonza 1H Core Ebitda Margin 29.6%

23 Jul 2025, 04:43 UTC

Earnings

Lonza: Margins Will Be Only Minimally Affected

23 Jul 2025, 04:42 UTC

Earnings

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23 Jul 2025, 04:42 UTC

Earnings

Lonza: This Is Mainly From Weakening of U.S. Dollar

23 Jul 2025, 04:38 UTC

Earnings

Lonza 1H Net Pft CHF426M

23 Jul 2025, 04:37 UTC

Earnings

Lonza Backs 2025 View for CHI Business

Peer Comparison

Price change

Lonza Group AG Forecast

Price Target

By TipRanks

37.73% upside

12 Months Forecast

Average 660 CHF 37.73%

High 670 CHF

Low 630 CHF

Based on 4 Wall Street analysts offering 12 month price targets forLonza Group AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Lonza Group AG - Dist in the past 3 months.

Sentiment

By Acuity

24 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.